Search Results - "Balstad, Trude Rakel"

A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer by Solheim, Tora S., Laird, Barry J.A., Balstad, Trude Rakel, Stene, Guro B., Bye, Asta, Johns, Neil, Pettersen, Caroline H., Fallon, Marie, Fayers, Peter, Fearon, Kenneth, Kaasa, Stein

“…Background Cancer cachexia is a syndrome of weight loss (including muscle and fat), anorexia, and decreased physical function. It has been suggested that the…”
Get full text

A cross-sectional study examining the prevalence of cachexia and areas of unmet need in patients with cancer by Vagnildhaug, Ola Magne, Balstad, Trude Rakel, Almberg, Sigrun Saur, Brunelli, Cinzia, Knudsen, Anne Kari, Kaasa, Stein, Thronæs, Morten, Laird, Barry, Solheim, Tora Skeidsvoll

“…Purpose The semantics of defining cancer cachexia over the last decade has resulted in uncertainty as to the prevalence. This has further hindered the…”
Get full text

Appetite Loss in Patients with Advanced Cancer Treated at an Acute Palliative Care Unit by Helgesen, Elisabeth Hagen, Ulevåg, Ragnhild, Solheim, Tora Skeidsvoll, Thronæs, Morten, Jakobsen, Gunnhild, Løhre, Erik Torbjørn, Balstad, Trude Rakel, Vagnildhaug, Ola Magne

“…Appetite loss is prevalent in patients with advanced cancer and negatively affects their quality of life. However, understanding of the factors associated with…”
Get full text

Pain management index (PMI)—does it reflect cancer patients’ wish for focus on pain? by Thronæs, Morten, Balstad, Trude Rakel, Brunelli, Cinzia, Løhre, Erik Torbjørn, Klepstad, Pål, Vagnildhaug, Ola Magne, Kaasa, Stein, Knudsen, Anne Kari, Solheim, Tora Skeidsvoll

“…Background The pain management index (PMI) was developed to combine information about the prescribed analgesics and the self-reported pain intensity in order…”
Get full text

Parenteral Nutrition in Palliative Cancer Care: Detrimental, Futile, or Beneficial? by Løhre, Erik Torbjørn, Solheim, Tora Skeidsvoll, Jakobsen, Gunnhild, Vagnildhaug, Ola Magne, Schmidberger Karlsen, Terese Louise, Habberstad, Ragnhild Hansdatter, Balstad, Trude Rakel, Thronæs, Morten

“…Palliative cancer care patients may live for a long time, but malnutrition worsens the prognosis. Parenteral nutrition (PN) is suitable for replenishing a…”
Get full text

Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series by McDonald, James, Sayers, Judith, Anker, Stefan D, Arends, Jann, Balstad, Trude Rakel, Baracos, Vickie, Brown, Leo, Bye, Asta, Dajani, Olav, Dolan, Ross, Fallon, Marie T, Fraser, Eilidh, Griel, Christine, Grzyb, Aleksandra, Hjermstad, Marianne, Jamal-Hanjani, Mariam, Jakobsen, Gunnhild, Kaasa, Stein, McMillan, Donald, Maddocks, Matthew, Philips, Iain, Ottestad, Inger O, Reid, Kieran F, Sousa, Mariana S, Simpson, Melanie R, Vagnildhaug, Ola Magne, Skipworth, Richard J E, Solheim, Tora S, Laird, Barry J A

“…In cancer cachexia trials, measures of physical function are commonly used as endpoints. For drug trials to obtain regulatory approval, efficacy in physical…”
Get full text

Deterioration in Muscle Mass and Physical Function Differs According to Weight Loss History in Cancer Cachexia by Stene, Guro Birgitte, Balstad, Trude Rakel, Leer, Anne Silja M, Bye, Asta, Kaasa, Stein, Fallon, Marie, Laird, Barry, Maddocks, Matthew, Solheim, Tora S

“…Muscle mass and physical function (PF) are common co-primary endpoints in cancer cachexia trials, but there is a lack of data on how these outcomes interact…”
Get full text

Coffee, broccoli and spices are strong inducers of electrophile response element-dependent transcription in vitro and in vivo - Studies in electrophile response element transgenic mice by Balstad, Trude Rakel, Carlsen, Harald, Myhrstad, Mari C.W, Kolberg, Marit, Reiersen, Hanne, Gilen, Lene, Ebihara, Kanae, Paur, Ingvild, Blomhoff, Rune

“…Scope: Cytoprotective gene products, e.g. phase II - and antioxidant enzymes, are important in cellular redox homeostasis. A common feature of these genes is…”
Get full text

Combining optimal nutrition and exercise in a multimodal approach for patients with active cancer and risk for losing weight: Rationale and practical approach by Solheim, Tora Skeidsvoll, Vagnildhaug, Ola Magne, Laird, Barry J., Balstad, Trude Rakel

“…•Weight loss and functional decline is a common and detrimental consequence of cancer.•Here we summarize the evidence for combined interventions targeting…”
Get full text

Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial by Solheim, Tora S, Laird, Barry J A, Balstad, Trude R, Bye, Asta, Stene, Guro, Baracos, Vickie, Strasser, Florian, Griffiths, Gareth, Maddocks, Matthew, Fallon, Marie, Kaasa, Stein, Fearon, Kenneth

“…Cancer cachexia is a multifactorial syndrome characterised by an ongoing loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional…”
Get more information

Multimodal nutrition/anabolic therapy for wasting conditions by Balstad, Trude Rakel, Kaasa, Stein, Solheim, Tora Skeidsvoll

“…PURPOSE OF REVIEWSignificant progress has been made in the field of defining and describing the pathophysiology of wasting conditions such as cachexia. The…”
Get full text

Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series by Brown, Leo R, Sousa, Mariana S, Yule, Michael S, Baracos, Vickie E, McMillan, Donald C, Arends, Jann, Balstad, Trude Rakel, Bye, Asta, Dajani, Olav, Dolan, Ross D, Fallon, Marie T, Greil, Christine, Hjermstad, Marianne Jensen, Jakobsen, Gunnhild, Maddocks, Matthew, McDonald, James, Ottestad, Inger, Phillips, Iain, Sayers, Judith, Simpson, Melanie Rae, Vagnildhaug, Ola Magne, Solheim, Tora S, Laird, Barry J, Skipworth, Richard J.E

“…Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or…”
Get full text

Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series by Yule, Michael S, Thompson, Joshua, Leesahatsawat, Khachonphat, Sousa, Mariana S, Anker, Stefan D, Arends, Jann, Balstad, Trude Rakel, Brown, Leo R, Bye, Asta, Dajani, Olav, Fallon, Marie, Hjermstad, Marianne Jensen, Jakobsen, Gunnhild, McDonald, James, McGovern, Josh, Roeland, Eric J, Sayers, Judith, Skipworth, Richard J.E, Ottestad, Inger, Philips, Iain, Simpson, Melanie Rae, Solheim, Tora S, Vagnildhaug, Ola Magne, McMillan, Donald, Laird, Barry J, Dolan, Ross D

“…Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered…”
Get full text

Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series by Hjermstad, Marianne Jensen, Jakobsen, Gunnhild, Arends, Jann, Balstad, Trude Rakel, Brown, Leo R, Bye, Asta, Coats, Andrew J.S, Dajani, Olav, Dolan, Ross D, Fallon, Marie T, Greil, Christine, Grzyb, Alexandra, Kaasa, Stein, Koteng, Lisa Heide, May, Anne M, McDonald, James, Ottestad, Inger, Philips, Iain, Roeland, Eric J, Sayers, Judith, Simpson, Melanie Rae, Skipworth, Richard J.E, Solheim, Tora S, Sousa, Mariana S, Vagnildhaug, Ola Magne, Laird, Barry J.A

“…The use of patient-reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients' self-report on health, functioning, wellbeing,…”
Get full text

Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series by Vagnildhaug, Ola Magne, Balstad, Trude Rakel, Ottestad, Inger, Bye, Asta, Greil, Christine, Arends, Jann, Baracos, Vickie, Brown, Leo R, Dajani, Olav, Dolan, Ross D, Fallon, Marie, Fraser, Eilidh, Grzyb, Aleksandra, Hjermstad, Marianne Jensen, Jakobsen, Gunnhild, Kaasa, Stein, McDonald, James, Philips, Iain, Sayers, Judith, Simpson, Melanie Rae, Sousa, Mariana S, Skipworth, Richard J.E, Laird, Barry J.A, Solheim, Tora S

“…There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical…”
Get full text

Patient interpretation of the Patient-Generated Subjective Global Assessment (PG-SGA) Short Form by Balstad, Trude R, Bye, Asta, Jenssen, Cathrine Rs, Solheim, Tora S, Thoresen, Lene, Sand, Kari

“…The Patient-Generated Subjective Global Assessment (PG-SGA) is a patient-reported instrument for assessment of nutrition status in patients with cancer…”
Get full text

Linguistic and content validation of the translated and culturally adapted PG-SGA, as perceived by Norwegian cancer patients and healthcare professionals by Henriksen, Christine, Thoresen, Lene, Fjøseide, Berit, Lorentzen, Sissi Stove, Balstad, Trude Rakel, Ottery, Faith D., Jager-Wittenaar, Harriët

“…The Scored Patient-Generated Subjective Global Assessment (PG-SGA©) is a validated nutritional screening, assessment, monitoring, and triage tool. When…”
Get full text

Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series by Vagnildhaug, Ola Magne, Balstad, Trude R., Ottestad, Inger, Bye, Asta, Greil, Christine, Arends, Jann, Baracos, Vickie, Brown, Leo R., Dajani, Olav F., Dolan, Ross D., Fallon, Marie, Fraser, Eilidh, Grzyb, Aleksandra, Hjermstad, Marianne J., Jakobsen, Gunnhild, Kaasa, Stein, McDonald, James, Philips, Iain, Sayers, Judith, Simpson, Melanie R., Sousa, Mariana S., Skipworth, Richard J.E., Laird, Barry J.A., Solheim, Tora S.

“…There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical…”
Get full text

Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series by Hjermstad, Marianne J., Jakobsen, Gunnhild, Arends, Jann, Balstad, Trude R., Brown, Leo R., Bye, Asta, Coats, Andrew J.S., Dajani, Olav F., Dolan, Ross D., Fallon, Marie T., Greil, Christine, Grzyb, Alexandra, Kaasa, Stein, Koteng, Lisa H., May, Anne M., McDonald, James, Ottestad, Inger, Philips, Iain, Roeland, Eric J., Sayers, Judith, Simpson, Melanie R., Skipworth, Richard J.E., Solheim, Tora S., Sousa, Mariana S., Vagnildhaug, Ola M., Laird, Barry J.A.

“…The use of patient‐reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients' self‐report on health, functioning, wellbeing,…”
Get full text

Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series by Brown, Leo R., Sousa, Mariana S., Yule, Michael S., Baracos, Vickie E., McMillan, Donald C., Arends, Jann, Balstad, Trude R., Bye, Asta, Dajani, Olav, Dolan, Ross D., Fallon, Marie T., Greil, Christine, Hjermstad, Marianne J., Jakobsen, Gunnhild, Maddocks, Matthew, McDonald, James, Ottestad, Inger O., Phillips, Iain, Sayers, Judith, Simpson, Melanie R., Vagnildhaug, Ola M., Solheim, Tora S., Laird, Barry J.A., Skipworth, Richard J.E.

“…Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or…”
Get full text